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*Talaromyces* (formerly *Penicillium*) *marneffei* is a pathogenic, thermal dimorphic fungus that causes systemic mycosis in Southeast Asia. *T. marneffei* infection is characterized by fungal invasion of multiple organ systems, especially blood, bone marrow, skin, lungs, and reticuloendothelial tissues, and is highly fatal, especially when diagnosis and treatment are delayed ([@R-2-1],[@R-2-2]). This disease is found predominantly in AIDS patients and occasionally those with cell-mediated immunodeficiencies involving the interleukin-12/interferon-γ (IFN-γ) signaling pathway, such as congenital STAT1 mutations or acquired autoantibodies against IFN-γ ([@R-2-1],[@R-2-3]--[@R-2-6]). The infection has rarely been reported among hematology patients, including those from disease-endemic regions ([@R-2-7],[@R-2-8]).

At Queen Mary Hospital in Hong Kong, a 1,600-bed university teaching hospital that has a hematopoietic stem cell transplantation service, where a wide range of invasive fungal infections have been observed ([@R-2-9],[@R-2-10]), only 3 cases of *T. marneffei* infection were encountered in \>2,000 hematology patients in the past 20 years, despite the long-standing availability of mycologic culture and serologic testing ([@R-2-7],[@R-2-8],[@R-2-11],[@R-2-12]). In contrast, the infection was commonly reported among AIDS patients ([@R-2-13]).

In the past 2 years, we have been alerted by 4 unprecedented cases of disseminated *T. marneffei* infection among non-AIDS hematology patients given targeted therapies, including monoclonal antibodies (mAbs) against CD20 and kinase inhibitors, which are being increasingly used in recent years. We report details for these 4 hematology case-patients. The study was approved by the institutional review board of The University of Hong Kong/Hospital Authority Hong Kong West Cluster in Hong Kong.

Case-Patient 1
==============

Patient 1 was a 56-year-old Filipino man with Waldenström macroglobulinemia, idiopathic thrombocytopenic purpura, and primary biliary cirrhosis. He had fever, night sweating, productive cough, and left facial pain for 1 week and bloody diarrhea for 2 days. He had previously received fludarabine, dexamethasone, and rituximab (mAb against CD20, 18 months earlier) for treatment of Waldenström macroglobulinemia ([Table 1](#T1){ref-type="table"}). The idiopathic thrombocytopenic purpura was controlled with intravenous immunoglobulin and maintenance prednisolone and mycophenolate sodium. A chest radiograph showed a small cavitary lesion in the right lower lobe. His symptoms and signs did not resolve after he received empirical intravenous imipenem/cilastatin and metronidazole ([Table 2](#T2){ref-type="table"}).

###### Characteristics of 4 case-patients with disseminated *Talaromyces marneffei* infection after targeted therapies\*

  Characteristic                                        Case-patient 1                                                                                                Case-patient 2                                                                                                                     Case-patient 3                                                    Case-patient 4
  ----------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------
  Age, y/sex                                            56/M                                                                                                          44/M                                                                                                                               63/M                                                              67/M
  Concurrent conditions                                 Waldenström macroglobulinemia, idiopathic thrombocytopenic purpura, primary biliary cirrhosis                 Chronic lymphocytic leukemia                                                                                                       Myelofibrosis with splenectomy, diabetes mellitus                 Acute myeloid leukemia, hypertension
  Targeted therapy                                      Rituximab                                                                                                     Rituximab and obinutuzumab                                                                                                         Ruxolitinib                                                       Sorafenib
  Action of therapy                                     mAb against CD20                                                                                              mAb against CD20                                                                                                                   JAK-1/2 inhibitor                                                 Multikinase inhibitor
  Time interval, mo†                                    18                                                                                                            14 (rituximab) and concomitant (obinutuzumab)                                                                                      Concomitant                                                       Concomitant
  Cumulative dose before *T. marneffei* infection       700 mg/dose iv x 4 doses                                                                                      700 mg/dose IV x 13 doses (rituximab) and 1,000 mg IV x 3 doses (obinutuzumab)                                                     10--20 mg 2×/d oral x 6.5 mo                                      400 mg 2×/d oral x 8 mo
  Other immunosuppressants (time interval, mo)†         Fludarabine and dexamethasone (39), prednisolone 10 mg/d and mycophenolate sodium 360 mg 2×/d (concomitant)   Fludarabine and cyclophosphamide (48), CHOP (36), bendamustine (13)                                                                None                                                              Mitoxantrone and etoposide (21), daunarubicin (20), clofarabine (18), azacitidine (15), decitabine (15), cytarabine (14)
  Clinical manifestations                               Terminal ileitis, cerebral abscesses, nasopharyngitis, and multiple cavitary lung lesions                     Marrow infiltration and fungemia                                                                                                   Right cervical lymphadenitis and multiple cavitary lung lesions   Fungemia
  Specimens positive for *T. marneffei*                 Feces, and terminal ileal and nasopharyngeal biopsy specimens                                                 Blood and bone marrow aspirate                                                                                                     Right cervical lymph node                                         Blood
  Highest serum antibody titer against *T. marneffei*   1:320                                                                                                         \<1:40                                                                                                                             1:320                                                             \<1:40
  Antifungal treatment (duration, mo)                   Amphotericin B (2 weeks) and voriconazole (\>21)                                                              Amphotericin B (2 weeks) and itraconaozle (5)                                                                                      Amphotericin B (2 weeks) and voriconazole (\>6)                   Amphotericin B (2 weeks) and voriconazole (\>5)
  Other opportunistic infections                        None                                                                                                          Bacteremia (*Mycobacterium chelonae*, *Enterococcus faecium*, and MRCNS), fungemia (*Candida glabrata*), HSV oral mucositis, PJP   Bacteremia (*Klebsiella pneumoniae*)                              Herpes zoster at right occiput
  Clinical outcome                                      Responded to antifungal treatment                                                                             Clearance of *T. marneffei* fungemia but died of MODS and multiple infections 5 mo after *T. marneffei* infection                  Responded to antifungal treatment                                 Responded to antifungal treatment

\*mAb, monoclonal antibody; JAK, Janus kinase; IV, intravenous; CHOP, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone; MRCNS, methicillin-resistant coagulase-negative *Staphylococcus*; HSV, herpes simplex virus; PJP, *Pneumocystis jiroveci* pneumonia; MODS, multiple organ dysfunction syndrome. †Time interval between end of therapy and onset of symptoms for *T. marneffei* infection.

###### Laboratory results for 4 case-patients with disseminated *Talaromyces marneffei* infection after targeted therapies\*

  Laboratory parameter            Case-patient 1                                                                                                                                            Case-patient 2                                                                                   Case-patient 3                                           Case-patient 4
  ------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ -------------------------------------------------------- --------------------------------------------------
  Hematologic†                                                                                                                                                                                                                                                                                                                                        
  Leukocytes, x 10^9^ cells/L     12.08                                                                                                                                                     0.91                                                                                             4.93                                                     33.79
  Neutrophils, x 10^9^ cells/L    11.01                                                                                                                                                     0.45                                                                                             3.11                                                     8.45 (with blasts)
  Lymphocytes, x 10^9^ cells/L    0.83 (CD4+: 315/µL)‡                                                                                                                                      0.45                                                                                             1.05                                                     9.12 (with blasts)
  Hemoglobin, g/dL                12.3                                                                                                                                                      10.3                                                                                             8.0                                                      9.2
  Platelets, x 10^9^/L            250                                                                                                                                                       5                                                                                                539                                                      15
  Biochemical†                                                                                                                                                                                                                                                                                                                                        
  Sodium, mmol/L                  136                                                                                                                                                       135                                                                                              139                                                      138
  Potassium, mmol/L               3.5                                                                                                                                                       4.1                                                                                              3.7                                                      4.4
  Creatinine, µmol/L              101                                                                                                                                                       111                                                                                              78                                                       92
  Albumin, g/L                    40                                                                                                                                                        32                                                                                               39                                                       37
  Globulin, g/L                   34                                                                                                                                                        36                                                                                               36                                                       39
  Total bilirubin, µmol/L         8                                                                                                                                                         9                                                                                                13                                                       19
  ALP, U/L                        234                                                                                                                                                       163                                                                                              112                                                      96
  ALT, U/L                        79                                                                                                                                                        20                                                                                               32                                                       61
  AST, U/L                        38                                                                                                                                                        9                                                                                                28                                                       123
  LDH, U/L                        209                                                                                                                                                       97                                                                                               352                                                      2,069
  Immunologic                                                                                                                                                                                                                                                                                                                                         
  Combined HIV antibody/antigen   Negative                                                                                                                                                  Negative                                                                                         Negative                                                 Negative
  Autoantibody against IFN-γ      Negative                                                                                                                                                  Negative                                                                                         Negative                                                 Negative
  Microbiologic                                                                                                                                                                                                                                                                                                                                       
  Blood culture                   No bacteria and fungi                                                                                                                                     *T. marneffei; Mycobacterium chelonae*, *Enterococcus faecium*, MRCNS, and *Candida glabrata*§   *Klebsiella pneumoniae*§                                 *T. marneffei*
  Bone marrow aspirate            ND                                                                                                                                                        *T. marrneffei*                                                                                  ND                                                       ND
  Sputum culture                  Negative for pathogenic bacteria, AFB, and fungi                                                                                                          Negative for pathogenic bacteria, AFB, and fungi                                                 Negative for pathogenic bacteria, AFB, and fungi         Negative for pathogenic bacteria, AFB, and fungi
  Urine culture                   No bacteria and fungi                                                                                                                                     No bacteria and fungi                                                                            No bacteria and fungi                                    No bacteria and fungi
  Stool culture                   *T. marneffei*; negative for pathogenic bacteria, including *Clostridium difficile* and AFB                                                               ND                                                                                               ND                                                       ND
  Serum CMV pp65 antigen          Negative                                                                                                                                                  Negative                                                                                         Negative                                                 Negative
  Other                           Stool for *C. difficile* toxin (negative); serum for *Entamoeba histolytica* antibody (negative); multiple blood smears for *Plasmodium* sp. (negative)   BAL: *Pneumocystis jiroveci* (smear-positive)                                                    Cervical lymph node: *T. marneffei* (culture-positive)   

\*ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; IFN-γ, interferon-γ; MRCNS, methicillin-resistant coagulase-negative *Staphylococcus*; ND, not done; AFB, acid-fast bacilli; CMV, cytomegalovirus; BAL, bronchoalveolar lavage. Reference ranges: leukocytes; 3.89--9.93 × 10^9^ cells/L; neutrophils, 2.01--7.42 × 10^9^ cells/L; lymphocytes, 1.06--3.61 × 10^9^ cells/L; hemoglobin, 13.3--17.7g/dL; platelets, 162--341 × 10^9^/L; sodium, 136--148 mmol/L; potassium, 3.6--5.0 mmol/L; creatinine, 67--109 µmol/L; albumin, 39--50 g/L; globulin, 24--37 g/L; total bilirubin, 4--23 µmol/L; ALP, 42--110 U/L; ALT, 8--58 U/L; AST, 5--38 U/L; LDH, 118--221 U/L. †Results at presentation. ‡Reference range of CD4+ lymphocyte count: 415--1,418 cells/µL. §Bacteremia caused by *M. chelonae, E. faecium,* MRCNS, and candidemia in case-patient 2, and bacteremia caused by *K. pneumoniae* in case-patient 3 occurred after recovery from *T. marneffei* infection and prolonged hospitalization.

A colonoscopy showed multiple shallow ulcers at the terminal ileum ([Figure 1](#F1){ref-type="fig"}). Histologic analysis of an ulcer biopsy specimen showed slough of an acutely inflamed ulcer but no microorganisms. However, histologic analysis of a specimen from a nasopharyngeal biopsy performed for persistent left facial pain showed abundant yeast cells engulfed by foamy macrophages ([Figure 2](#F2){ref-type="fig"}). Culture of terminal ileal ulcer biopsy specimens, stool samples, and nasopharyngeal biopsy specimens yielded *T. marneffei*. A contrast-enhanced cranial computed tomography (CT) scan showed 2 lesions (3--4-mm) with rim enhancement and perifocal edema at the right occipital and left parieto-occipital lobes. A thoracic CT scan showed 2 cavitary lesions (4--8 mm) in the right upper and lower lobes.

![Multiple, shallow, oozing ulcers at the terminal ileum (arrows) detected by colonoscopy on day 4 of hospitalization for case-patient 1, who had a disseminated infection with *Talaromyces marneffei*.](15-0138-F1){#F1}

![Nasopharyngeal biopsy specimen from case-patient 1, who had a disseminated infection with *Talaromyces marneffei*. A) Grocott silver staining showing abundant yeast cells (arrows) with central septa 4--5 µm in diameter. B) Hematoxylin and eosin staining showing necrotic material admixed with blood and fibrin with aggregates of foamy macrophages (arrow). Scale bars indicate 5 μm.](15-0138-F2){#F2}

Immunologic testing showed that the patient was negative for HIV and autoantibodies against IFN-γ. His CD3+ and CD8+ counts were within references ranges, but he had mild CD4+ lymphopenia ([Table 2](#T2){ref-type="table"}). His fever and symptoms resolved with after 2 weeks of treatment with intravenous liposomal amphotericin B, followed by oral voriconazole. Reassessment colonoscopy (at 2 months) and CT scan (at 6 months) showed complete resolution of all lesions.

Case-Patient 2
==============

Patient 2 was a 44-year-old Chinese man who had fever for 2 days. He had previously received chemotherapy and mAbs against CD20 (rituximab, 14 months earlier; obinutuzumab, concomitant) for refractory chronic lymphocytic leukemia (CLL) involving bone marrow ([Table 1](#T1){ref-type="table"}). He was empirically given intravenous piperacillin/tazobactam and anidulafungin ([Table 2](#T2){ref-type="table"}). Histologic analysis of a trephine biopsy specimen showed persistent CLL with plasmacytic differentiation, and Grocott staining showed yeasts with central septa in small clusters. Culture of peripheral blood and bone marrow aspirate yielded *T. marneffei*. A change in antifungal treatment to intravenous amphotericin B led to defervescence and clearance of fungemia. He was given oral itraconazole as maintenance therapy. He remained well until 2 months later when he was hospitalized for deteriorating CLL complicated by neutropenic fever with multiorgan failure caused by other opportunistic infections ([Table 1](#T1){ref-type="table"}). He died 5 months after the episode of disseminated *T. marneffei* infection.

Case-Patient 3
==============

Patient 3 was a 63-year-old Chinese man with myelofibrosis and well-controlled diabetes mellitus. He had intermittent fever, right cervical lymphadenopathy, and productive cough for 4 months. He was given ruxolitinib (kinase inhibitor) 6 months before symptom onset because of transfusion-dependent myelofibrosis despite splenectomy 4 years earlier ([Table 1](#T1){ref-type="table"}). A chest radiograph and thoracic CT scan showed multiple cavitary lesions and consolidation. Bronchoalveolar lavage was negative for bacteria, fungi, and mycobacteria. A serum cryptococcal antigen test result was negative. He was empirically given intravenous imipenem/cilastatin and oral doxycycline, but his symptoms persisted. A right cervical lymph node culture yielded *T. marneffei*. His symptoms and radiologic abnormalities resolved after treatment with intravenous amphotericin B for 2 weeks, followed by oral voriconazole for 6 months.

Case-Patient 4
==============

Patient 4 was a 67-year-old Chinese man with acute myeloid leukemia and hypertension. He had fever and malaise for 2 days without localizing signs. He had been given sorafenib (kinase inhibitor) 8 months earlier for chemotherapy-refractory acute myeloid leukemia ([Table 1](#T1){ref-type="table"}). His fever did not respond to intravenous meropenem. Subsequently, 2 sets of blood cultures yielded *T. marneffei*. He was given intravenous amphotericin B for 2 weeks, followed by oral voriconazole. He remained well at follow-up 6 months after symptom onset.

Discussion
==========

*T. marneffei* infection is an emerging complication in hematology patients receiving targeted therapies. Historically, *T. marneffei* infection has rarely been seen in non-AIDS patients, even in disease-endemic regions. During 1994--2014, only 3 other cases were observed in our hematology patients ([@R-2-7],[@R-2-8],[@R-2-11]). None of 47 patients with *T. marneffei* infection in another large local case series during 1994--2004 had hematologic disease ([@R-2-13]). In the past 20 years, there has been no change in methods for laboratory diagnosis of *T. marneffei* infection or a marked increase in the number of hematology patients in our hospital. Therefore, these 4 cases indicate an increase in the incidence of *T. marneffei* infection in these patients. Although other immunosuppressants given to case-patients 1, 2, and 4 might have contributed to overall immunosuppression, none of these immunosuppressants, which have been used for years, have been associated with *T. marneffei* infection. Because use of targeted therapies is increasing in diverse patient groups, clinicians should be aware of this emerging complication, especially in patients from disease-endemic regions who have received these therapies with other immunosuppressants.

The exact mechanisms through which these targeted therapies lead to *T. marneffei* infection remain incompletely understood. Rituximab and obinutuzumab (used by case-patients cases 1 and 2) are mAbs against CD20 that predominantly target B cells. Unlike T cells, the role of B cell--mediated humoral response in *T. marneffei* infection is poorly defined. Although case-patient 1 had mild CD4+ lymphopenia probably related to concomitant use of prednisolone and mycophenolate sodium, *T. marneffei* infection is rarely seen in patients with CD4+ counts \>300/µL ([@R-2-1]). We postulate that B cell dysfunction might have impaired production of neutralizing antibodies against key virulence factors of *T. marneffei* or might involve impairment of cytokine-producing B cells, which are essential for T helper cell function ([@R-2-14]).

More severe infections with fungemeia and bone marrow involvement developed in case-patients 2 and 4, who had undetectable levels of serum antibodies against *T. marneffei*. Correspondingly, case-patients 1 and 3, who had antibody titers \>1:320, did not have positive blood culture results ([Table 2](#T2){ref-type="table"}). Symptoms developed in case-patient 1 more than a 1 year after he completed therapy with mAbs against CD20. This finding might be related to long-lasting B cell--depleting effects of mAbs against CD20 ([@R-2-15]).

Regarding kinase inhibitors (used by cases-patients 3 and 4), ruxolitinib is a selective Janus kinase (JAK)-1/2 inhibitor that prevents signal transduction for type I/II cytokines, including IFN-γ, by interfering with the JAK-STAT signaling pathway. Use of ruxolitinib has been associated with opportunistic infections caused by intracellular pathogens, such as *Mycobacterium tuberculsosis* and *Cryptococcus neoformans* ([@R-2-16],[@R-2-17]). Similarly, patients with impaired JAK-STAT signaling, but not those with diabetes mellitus or splenectomy (case-patient 3), are predisposed to *T. marneffei* infection ([@R-2-6]). Sorafenib is a multikinase inhibitor with various immunomodulatory effects, including impaired T-cell response and proliferation and reduced IFN-γ production ([@R-2-18]). These immune defects have been associated with reactivation of latent tuberculosis and might also predispose patients to opportunistic infections caused by intracellular organisms such as *T. marneffei* ([@R-2-18]).

The recognition of disseminated *T. marneffei* infection as an emerging complication in non-AIDS patients treated with targeted therapy has major public health implications. In regions to which *T. marneffei* infection is endemic, serologic surveillance for patients receiving targeted therapy might be useful in the early diagnosis of *T. marneffei* infection, as in the case of AIDS patients ([@R-2-19]). In non-endemic regions, such as the United States, clinicians should be vigilant of this infrequent infection in at-risk hematology patients who have resided in or are returning from disease-endemic areas.
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**1. According to the case series report by Chan and colleagues, which of the following statements about the clinical and epidemiologic characteristics of *Talaromyces marneffei* infection is correct?**A. *T. marneffei* infection is the most important pathogenic thermal dimorphic fungus causing systemic mycosis in Southeast AsiaB. *T. marneffei* infection is typically limited to the gastrointestinal and/or urinary tractC. *T. marneffei* infection is usually self-limited with a good prognosis for recoveryD. *T. marneffei* infection is common among non-AIDS hematology patients**2. Your patient is a 57-year-old Chinese man with acute myeloid leukemia and fever. According to the case series report by Chan and colleagues, which of the following statements about the recent emergence of disseminated *T. marneffei* infection in non-AIDS patients with hematologic malignant neoplasms treated with targeted therapies is correct?**A. The appearance of 4 cases in the past 2 years is the result of a change in the methodologies of a laboratory diagnosis of *T. marneffei* infectionB. The appearance of 4 cases in the past 2 years is the result of a dramatic increase in the number of hematology patients at the investigators\' hospitalC. Recent emergence of disseminated *T. marneffei* infection is most likely because of overall immunosuppressionD. Recent emergence of disseminated *T. marneffei* infection is most likely because of targeted therapies, such as anti-CD20 monoclonal antibodies and kinase inhibitors**3. According to the case series report by Chan and colleagues, which of the following statements about possible mechanisms of action underlying disseminated *T. marneffei* infection in non-AIDS patients with hematologic malignant neoplasms treated with targeted therapies would most likely be accurate?**A. Rituximab and obinutuzumab used in 2 cases are anti-CD20 monoclonal antibodies that predominantly target T cellsB. *T. marneffei* infection is usually seen at CD4+ counts of more than 300/µLC. Patients with B-cell dysfunction may have impaired production of neutralizing antibodies against key virulence factors of *T. marneffei* D. The investigators do not suggest any role of cytokine-producing B-cells
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